All stock lists
Unlock the score
Charles River Laboratories International, Inc. (New York Stock Exchange:CRL)
US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
353.77+8.40 (+2.43%)
Market cap
$17.0B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 23, 2000
Website
Insider Score
/ 100
CRL Insider Score
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
CRL analyst forecast
CRL analyst consensus
Moderate Buy10 ratings
Buy 9 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CRL 12-month price target
$328.00-8.2% downsideaverage of 4 firms
$357.00High
$295.00Low
Best analysts covering CRL
- Barclays100%success rate · 1 call
- Citigroup75%success rate · 4 calls
- Evercore ISI Group60%success rate · 5 calls
- Jefferies50%success rate · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CRL analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-10-13 |
| UBS | — | $357.00 | +20.6% | — | 2026-09-30 | |
| Jefferies | Buy | $340.00 | +16.1% | Reiterated | 2026-09-28 | |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-09-25 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-09-25 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-09-25 |
| Deutsche Bank | Buy | $320.00 | +9.9% | Reiterated | 2026-09-25 | |
| — | Baird | Outperform | — | — | Reiterated | 2026-09-25 |
| Mizuho | Neutral | $295.00 | +0.2% | Reiterated | 2026-09-25 | |
| — | Barclays | Overweight | — | — | Reiterated | 2026-09-25 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-09-11 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-08-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-08-07 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2026-08-06 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-08-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-08-06 |
| — | CLSA | Hold | — | — | Downgraded | 2026-07-20 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-07-13 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-09 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2026-06-17 |
| — | CLSA | Outperform | — | — | Upgraded | 2026-05-29 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-08 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-05-08 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-14 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-04-13 |
| — | UBS | Neutral | — | — | Reiterated | 2026-02-25 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-02-20 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-02-20 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-02-19 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-02-19 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-01-16 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-01-13 |
| — | Mizuho | Neutral | — | — | Reiterated | 2025-12-18 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-12-15 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-12-15 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2025-11-11 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-11-10 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-11-06 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-11-06 |
| — | Baird | Outperform | — | — | Upgraded | 2025-11-06 |
| — | Mizuho | Neutral | — | — | Reiterated | 2025-10-17 |
| — | William Blair | Outperform | — | — | Upgraded | 2025-10-06 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2025-10-03 |
| — | Barclays | Overweight | — | — | Upgraded | 2025-10-02 |
| — | Jefferies | Buy | — | — | Upgraded | 2025-09-09 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2025-08-08 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-08-07 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-08-07 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2025-07-09 |
| — | Citigroup | Buy | — | — | Upgraded | 2025-07-09 |
| — | Redburn Atlantic | Buy | — | — | Upgraded | 2025-05-23 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-05-08 |
| — | Baird | Neutral | — | — | Reiterated | 2025-05-08 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-04-10 |
| — | Mizuho | Neutral | — | — | Reiterated | 2025-04-09 |
| — | Goldman Sachs | Neutral | — | — | Downgraded | 2025-03-21 |
| — | Citigroup | Neutral | — | — | Upgraded | 2025-03-04 |
| — | Redburn Atlantic | Neutral | — | — | Upgraded | 2025-03-03 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-02-20 |
| — | Baird | Neutral | — | — | Reiterated | 2025-02-20 |
CRL earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-18 | 2.33 | 2.39 | $987.0M | $994.2M |
| 2026-05-07 | 1.96 | 2.06 | $977.5M | $995.8M |
| 2026-08-05 | 2.74 | 3.02 | $977.2M | $1.00B |
| 2026-11-04 | 2.97 | 0.00 | $960.4M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.